Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Journal of the American College of Nutrition

Volumn 35, Issue 4, 2016, Pages 346-353

  Farsi, Farnaz ^a   Mohammadshahi, Majid ^a   Alavinejad, Pezhman ^a   Rezazadeh, Afshin ^a   Zarei, Mehdi ^a   Engali, Kambiz Ahmadi ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

adipocytokines; coenzyme Q10 (CoQ10); inflammation; nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 6; LEPTIN; LIVER ENZYME; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR; UBIQUINONE;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; DIETARY SUPPLEMENT; ENZYMOLOGY; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADIPOKINES; ADIPONECTIN; ADULT; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFLAMMATION; LEPTIN; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLACEBOS; TUMOR NECROSIS FACTOR-ALPHA; UBIQUINONE;

EID: 84936976914     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2015.1021057     Document Type: Article

References (43)

1. M.H.Jarrar, A.Baranova, R.Collantes, B.Ranard, M.Stepanova, C.Bennett, Y.Fang, H.Elariny, Z.Goodman, V.Chandhoke, Z.M.Younossi: Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27:412–421, 2008.
2. D.A.de Luis, R.Aller, O.Izaola, M.Gonzalez Sagrado, R.Conde: Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 25:730–735, 2010.
3. C.D.Williams, J.Stengel, M.I.Asike, D.M.Torres, J.Shaw, M.Contreras, C.L.Landt, S.A.Harrison: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140(1):124–131, 2011.
4. E.Hui, A.Xu, H.B.Yang, K.S.Lam: Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes Investig 4:413–425, 2013.
5. X.Buqué, P.Aspichueta, B.Ochoa: Molecular basis of obesity-related hepatic steatosis. Rev Esp Enferm Dig 100:565–578, 2008.
6. S.Y.Oh, Y.K.Cho, M.S.Kang, T.W.Yoo, J.H.Park, H.J.Kim, D.I.Park, C.I.Sohn, W.K.Jeon, B.I.Kim, B.H.Son, J.H.Shin: The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 55:1604–1609, 2006.
7. C.Finelli, G.Tarantino: Is there any consensus as to what diet or lifestyle approach is the right one for NAFlD patients? J Gastrointestin Liver Dis 21:293–302, 2012.
8. F.Marra, A.Gastaldelli, G.Svegliati Baroni, G.Tell, C.Tiribelli: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72–81, 2008.
9. M.B.Vos, C.J.McClain: Nutrition and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 10:308–315, 2008.
10. C.Pagano, G.Soardo, W.Esposito, F.Fallo, L.Basan, D.Donnini, G.Federspil, L.A.Sechi, R.Vettor: Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113–118, 2005.
11. M.Başaranoğlu, N.Örmeci: Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol 25:127–132, 2014.
12. K.J.Schwenger, J.P.Allard: Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 20:1712–1723, 2014.
13. A.A.Franke, C.M.Morrison, J.L.Bakke, L.J.Custer, W.Li, R.V.Cooney: Coenzyme Q10 in human blood: Native levels and determinants of oxidation during processing and storage. Free Radic Biol Med 48:1610–1617, 2010.
14. S.A.Asker: Impact of coenzyme Q10 on the histological structure and immunohistochemical localization of leptin in the ampulla of rat oviduct after monosodium glutamate administration. Egyptian Journal of Histology 34:365–376, 2011.
15. M.A.Alam, M.M.Rahman: Mitochondrial dysfunction in obesity: potential benefit and mechanism of co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord 13:60, 2014.
16. M.Moazen, Z.Mazloom, M.H.Dabbaghmanesh, A.Ahmadi: Effect of CoQ10 supplementation on blood pressure, inflammation, and lipid profile in type 2 diabetics. Iranian Journal of Nutrition Sciences & Food Technology 8:145–153, 2013.
17. M.C.Carmona, P.Lefebvre, B.Lefebvre, A.Galinier, A.Benani, Y.Jeanson, K.Louche, S.Flajollet, A.Ktorza, C.Dacquet, L.Pénicaud, L.Casteilla: Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes (Lond) 33:204–211, 2009.
18. B.Fuller, D.Smith, A.Howerton, D.Kern: Anti-inflammatory effects of CoQ10 and colorless carotenoids. J Cosmet Dermatol 5:30–38, 2006.
19. F.M.Sohet, A.M.Neyrinck, B.D.Pachikian, F.C.de Backer, L.B.Bindels, P.Niklowitz, T.Menke, P.D.Cani, N.M.Delzenne: Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol 78:1391–1400, 2009.
20. A.A.Fouad, I.Jresat: Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity. Environ Toxicol Pharmacol 33:158–167, 2012.
21. C.Schmelzer, I.Lindner, G.Rimbach, P.Niklowitz, T.Menke, F.Döring: Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 32:179–183, 2008.
22. E.Bravo, S.Palleschi, B.Rossi, M.Napolitano, L.Tiano, E.D’Amore, K.M.Botham: Coenzyme Q metabolism is disturbed in high fat diet-induced non alcoholic fatty liver disease in rats. Int J Mol Sci 13:1644–1657, 2012.
23. F.Lirussi, L.Azzalini, S.Orando, R.Orlando, F.Angelico: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 1:1–35, 2007.
24. M.Hashemi,, G.Bahari, S.Ghavami: Coenzyme Q10 may be effective in the treatment of non alcoholic fatty liver disease (NAFLD). Iranian Journal of Medical Hypotheses and Ideas 2:1–9, 2008.
25. H.Gökbel, H.S.Gergerlioglu, N.Okudan, I.Gül, S.Büyükbaş, M.Belviranli: Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men. J Med Food 13:216–218, 2010.
26. B.J.Lee, Y.F.Tseng, C.H.Yen, P.T.Lin: Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J 12:1–9, 2013.
27. B.J.Lee, Y.C.Huang, J.U.Shu, S.J.Chen, P.T.Lin: Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28:767–772, 2012.
28. M.Sanoobar, S.Eghtesadi, A.Azimi, M.Khalili, B.Khodadadi, S.Jazayeri, M.R.Gohari, N.Aryaeian: Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci 18:169–176, 2015.
29. C.Schmelzer, I.Lindner, G.Rimbach, P.Niklowitz, T.Menke, F.Döring: Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 32:179–183, 2008.
30. C.Kishimoto, T.Nobuyoshi, N.Yukie, M.Miki: Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol 42:588–592, 2003.
31. M.Obika, H.Noguchi: Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012:1–12, 2012.
32. J.K.Dowman, J.W.Tomlinson, P.N.Newsome: Pathogenesis of non-alcoholic fatty liver disease. Q J Med 103:71–83, 2010.
33. X.D.Huang, Y.Fan, H.Zhang, P.Wang, J.P.Yuan, M.J.Li, X.Y.Zhan: Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 14:2888–2893, 2008.
34. S.Onur, P.Niklowitz, G.Gunnar Jacobs, U.Nöthlings, W.Lieb, T.Menke, F.Döring: Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans. BMC Res Notes 7:427, 2014.
35. S.Yuvaraj, V.G.Premkumar, P.Shanthi, K.Vijayasarathy, S.G.Gangadaran, P.Sachdanandam: Effect of coenzyme Q(10), riboflavin and niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. Breast Cancer Res Treat 114:377–384, 2009.
36. A.M.Abbas, H.F.Sakr: Simvastatin and vitamin E effects on cardiac and hepatic oxidative stress in rats fed on high fat diet. J Physiol Biochem 69:737–750, 2013.
37. M.A.Jiménez-Santos, I.E.Juárez-Rojop, C.A.Tovilla-Zárate, M.T.Espinosa-García, M.A.Juárez-Oropeza, T.Ramón-Frías, D.Y.Bermúdez-Ocaña, J.C.Díaz-Zagoya: Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. Lipids Health Dis 13:1–22, 2014.
38. A.Sa, L.Faddah, A.Abdel-baky, A.Bayoumi: Protective effect of L-carnitine and coenzyme Q10 on CCl4-induced liver injury in rats. Sci Pharm 78:881–896, 2010.
39. K.Sumimoto, K.Inagaki, H.Ito, S.Marubayashi, K.Yamada, T.Kawasaki, K.Dohi: Ischemic damage prevention by coenzyme Q10 treatment of the donor before orthotopic liver transplantation: biochemical and histologic findings. Surgery 102:821–827, 1987.
40. S.A.Esfahani, E.Esmaeilzadeh, F.Bagheri, Y.Emami, M.Farjam: The effect of co-enzyme Q10 on acute liver damage in rats, a biochemical and pathological study. Hepat Mon 13:1–2, 2013.
41. H.K.Choi, Y.R.Pokhare, S.C.Lim, H.K.Han, C.S.Ryu, S.K.Kim, M.K.Kwak, K.W.Kang: Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-β1 expression. Toxicol Appl Pharmacol 240:377–384, 2009.
42. M.J.Czaja, F.R.Weiner, K.C.Flanders, M.A.Giambrone, R.Wind, L.Biempica, M.A.Zern: In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 108:2477–2482, 1989.
43. H.A.Saleh, A.H.Abu-Rashed: Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis 16:425–426, 2007.